Drugs / Capadenoson
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00518921 | Mar → Nov 2008 | intermediate coronary syndrome | Bayer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00568945 | Jan → Nov 2008 | atrial fibrillation | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Capadenoson | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00518921 ↗ |
| Known as | BAY 68-4986 | “Capadenoson (BAY 68-4986)” NCT00518921 ↗1“Capadenoson (BAY68-4986)” NCT00568945 ↗ |
| Action | Activate | “Adenosine A1 receptor partial agonist” CHEMBL3235279 ↗ |
| Modality | Small molecule | — CHEMBL3235279 ↗ |
| Route | Oral | “BAY 68-4986 taken orally” NCT00518921 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor partial agonist” CHEMBL3235279 ↗ |